Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Pritzlaff

Anesthesiology Redwood City, CA Medical Doctor

NPI 1912061805 CMS profile 1271262

450 Broadway St, Pavilion A 1St Floor Mc 5340, Redwood City, CA 94063

Open in the dashboard

General payments

$165,131

256 records reported · program years 2019–2025

Research payments

$6,615

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott Pritzlaff of Redwood City, CA is reported in the CMS Open Payments database as having received $165,131 across 256 general payments and $6,615 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $61,105 90
2025 Research $6,615 3
2024 General $34,650 63
2023 General $20,530 42
2022 General $16,404 30
2021 General $11,893 18
2020 General $20,414 9
2019 General $135 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Pritzlaff
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Scott Pritzlaff were reported at $61,105. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Scott Pritzlaff Anesthesiology median Middle half National median
2019 $135 $72 $23–$151 $163
2020 $20,414 $36 $17–$120 $114
2021 $11,893 $49 $21–$135 $132
2022 $16,404 $52 $22–$144 $149
2023 $20,530 $53 $23–$143 $160
2024 $34,650 $55 $25–$150 $164
2025 $61,105 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. SPR Therapeutics, Inc $127,627 130 payments
  2. Nalu Medical, Inc. $19,948 16 payments
  3. Bioventus LLC $7,599 10 payments
  4. Medtronic, Inc. $5,300 33 payments
  5. Abbott Laboratories $1,620 21 payments
  6. Boston Scientific Corporation $1,581 16 payments
  7. BIOTRONIK NRO, Inc. $516 9 payments
  8. Nevro Corp. $393 8 payments
  9. MML US, Inc. $203 2 payments
  10. Globus Medical, Inc. $93 3 payments
  11. Other $251 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $112,416 45 payments
  2. Travel and Lodging $27,663 55 payments
  3. Food and Beverage $17,509 152 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,543 4 payments
Products named General payments · program years 2019–2025
  1. SPRINT PNS System $127,627 130 payments
  2. Nalu Neurostimulation System $19,948 16 payments
  3. Stimrouter Implantable Kit $7,546 9 payments
  4. INTELLIS ADAPTIVESTIM $3,662 21 payments
  5. Superion Indirect Decompression System $869 8 payments
  6. ETERNA $503 4 payments
  7. PROCLAIM $325 6 payments
  8. BIOTRONIK $275 5 payments
  9. Senza $273 6 payments
  10. INCEPTIV $204 6 payments
  11. Other $2,128 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $6,615 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

61

Median for Anesthesiology: 322

Drug cost

$965

Median for Anesthesiology: $8,738

Branded share of claims

0%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Duloxetine Hcl Generic 37 $673
Gabapentin Generic 24 $292

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$89,754

Medicare's payments for the services billed

Medicare patients

318

Average age 73

Services billed

1,333

181 women, 137 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Diabetes 29%
Depression 29%
Chronic kidney disease 25%
Ischemic heart disease 23%
Osteoporosis 20%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

259 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record